Answers are grounded in this paper and cite their sources.
Background Pregnancy- and perinatal-related reporting signals for anti-seizure medications (ASMs) require assessment against other reporting sources and clinical studies. Objective The aim in this study was to assess selected ASM reporting hypotheses across US Food and Drug Administration Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Report database (JADER), and clinical studies and identify priorities for clinical investigation. Methods Deduplicated FAERS reports from 2004Q1–2026Q2 were screened. Eligibility required female sex, an epilepsy-related indication, and a suspect ASM: carbamazepine, lamotrigine, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, or valproate. Maternal pregnancy exposure was not verified. Reporting odds ratios (RORs) compared indexed-ASM primary/secondary-suspect reports with other-target-ASM reports lacking indexed-suspect entries. Signals required at least three drug-outcome reports and a lower 95% confidence interval (CI) bound above 1. Three exploratory pairs and one valproate positive control underwent seven core FAERS sensitivity analyses, JADER analysis, and qualitative clinical evidence synthesis. Sensitivity analyses excluded any-role indexed-drug mentions from comparators and required drug-linked epilepsy indications. Results Among 42,290 eligible reports, 54 drug-preferred term signals yielded 27 clinical candidates after exclusions and grouping. Three exploratory pairs and one positive control underwent cross-source evaluation. Levetiracetam–preterm delivery (481 reports; ROR 2.68, 95% CI 2.24–3.21) retained its signal in all seven core analyses and under the comparator and indication restrictions. It was the only exploratory pair meeting the signal criteria in both databases. The JADER estimate was very imprecise, based on eight indexed-drug and one comparator outcome report (ROR 18.61, 95% CI 2.33–148.99). Available direct clinical estimates remained inconclusive. Levetiracetam–pregnancy loss and lamotrigine–cardiac congenital anomaly lacked consistent external corroboration. The valproate–central nervous system congenital anomaly positive control was supported by clinical studies, while FAERS findings were unstable and JADER reporting was sparse. Conclusion Levetiracetam–preterm delivery remains a reporting hypothesis with an unconfirmed clinical association. Cohorts comparing monotherapy regimens with verified pregnancy exposure are warranted. The other exploratory findings also remain hypotheses.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: